Antoine Rauch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antoine Rauch has a total of 488 co-authors. Here are the top co-authors by number of shared publications:
- Sophie Susen
Université de Lille, INSERM, Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Unit 1011-European Genomic Institute for Diabetes, Lille, France
33 shared publications - Eric Van Belle
Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France
17 shared publications - Peter J. Lenting
Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Hémostase inflammation thrombose U1176, 94276, Le Kremlin-Bicêtre
15 shared publications - André Vincentelli
Heart and Lung Institute, Cardiac Surgery Department, CHU Lille, F-59000
11 shared publications - Bart Staels
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
10 shared publications Emmanuelle Jeanpierre
Hematology and Transfusion Department, INSERM U1011, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Université de Lille, Lille, France
9 shared publications
Latest Publications
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7177-7186
Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa
The Efanesoctocog Compassionate Hemophilia study (Méthodologie de Référence-004, number DEC24-269) provides a real-world evaluation of efanesoctocog alfa (efa), a first-in-class ultralong-acting factor VIII (FVIII) concentrate, within the French compassionate access authorization (CAA) framework. It aims to characterize the unmet medical needs leading to CAA requests and evaluate the hemostatic efficacy and biological monitoring of efa prophylaxis. This multicenter study included 50 patients with hemophilia A (84% severe; median age, 31 years), including 9 with inhibitor history. Although 54% of patients switched from FVIII prophylaxis, 46% of patients transitioned from emicizumab because of persistent breakthrough bleeding (88%) and complex multifactorial scenarios (76%). Over a median follow-up of 9 months, weekly efa prophylaxis resulted in a significant 89% reduction in treated bleeds (P< .001) and an 85% reduction in joint bleeds (P< .001) in the total population. This clinical benefit remained consistent across exploratory subgroups, including patients who were previously on emicizumab. No new-onset inhibitors occurred. Biologically, the median centralized day-7 trough level was 7 IU/dL using a drug-calibrated bovine chromogenic substrate assay (CSA, n = 31). However, a significant discrepancy was observed in paired comparisons (n = 18), where local 1-stage assays (OSAs) yielded a median trough level of 14 IU/dL, compared with a centralized CSA median of 7 IU/dL (P< .001). Notably, this divergence occurred across various local reagents considered acceptable alternatives to Actin FSL for efa monitoring. In conclusion, efa effectively addresses complex unmet needs, including those of emicizumab-treated patients. However, the discrepancy between results of local OSAs and drug-calibrated CSA highlights challenges in laboratory monitoring.
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7177-7186
Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa
The Efanesoctocog Compassionate Hemophilia study (Méthodologie de Référence-004, number DEC24-269) provides a real-world evaluation of efanesoctocog alfa (efa), a first-in-class ultralong-acting factor VIII (FVIII) concentrate, within the French compassionate access authorization (CAA) framework. It aims to characterize the unmet medical needs leading to CAA requests and evaluate the hemostatic efficacy and biological monitoring of efa prophylaxis. This multicenter study included 50 patients with hemophilia A (84% severe; median age, 31 years), including 9 with inhibitor history. Although 54% of patients switched from FVIII prophylaxis, 46% of patients transitioned from emicizumab because of persistent breakthrough bleeding (88%) and complex multifactorial scenarios (76%). Over a median follow-up of 9 months, weekly efa prophylaxis resulted in a significant 89% reduction in treated bleeds (P< .001) and an 85% reduction in joint bleeds (P< .001) in the total population. This clinical benefit remained consistent across exploratory subgroups, including patients who were previously on emicizumab. No new-onset inhibitors occurred. Biologically, the median centralized day-7 trough level was 7 IU/dL using a drug-calibrated bovine chromogenic substrate assay (CSA, n = 31). However, a significant discrepancy was observed in paired comparisons (n = 18), where local 1-stage assays (OSAs) yielded a median trough level of 14 IU/dL, compared with a centralized CSA median of 7 IU/dL (P< .001). Notably, this divergence occurred across various local reagents considered acceptable alternatives to Actin FSL for efa monitoring. In conclusion, efa effectively addresses complex unmet needs, including those of emicizumab-treated patients. However, the discrepancy between results of local OSAs and drug-calibrated CSA highlights challenges in laboratory monitoring.
- 5 May 2026
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 210 (5) , 571-578
La thérapie génique dans l’hémophilie
- 5 May 2026
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 210 (5) , 571-578
La thérapie génique dans l’hémophilie
- 20 April 2026
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 210 (5) , 665-666
Discussion à propos de la communication : « La thérapie génique dans l’hémophilie »
- 20 April 2026
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 210 (5) , 665-666
Discussion à propos de la communication : « La thérapie génique dans l’hémophilie »
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Protéolyse du facteur Willebrand et cardiopathies à forces de cisaillement élevées : nouvelles approches diagnostiques et thérapeutiques
Protéolyse du facteur von Willebrand et cardiopathies à forces de cisaillement élevées: nouvelles approches diagnostiques et thérapeutiques Dans la première partie de ce travail, nous mettons en évidence l’intérêt d’une immunothérapie spécifique à base d’anticorps monoclonal pour la prévention de la dégradation du facteur von Willebrand (VWF) sous assistance circulatoire mécanique à flux continu. Via un anticorps monoclonal murin ciblant le domaine D4 du VWF et inhibant partiellement l’interaction VWF-ADAMTS13, une inhibition partielle de la dégradation du VWF est observée sur sang total dans un modèle ex-vivo d’assistance circulatoire mécanique.Dans la seconde partie, nous avons étudié l’influence de soudaines variations de l’intensité des forces de cisaillement sur la multimérisation du VWF dans 3 modèles in-vivo: un modèle lapin de sténose de l’aorte ascendante, à l’initiation d’une assistance ventriculaire gauche par une pompe à flux continu chez des patients en insuffisance cardiaque terminale et lors d’un remplacement valvulaire aortique par voie percutané chez des patients avec un rétrécissement aortique sévère. Les variations observées du profil multimérique sont très dynamiques survenant quelques minutes après les modifications des conditions de flux. Notre étude met ainsi en évidence une nouvelle application potentielle du VWF comme biomarqueur d’anomalies de flux dans les cardiopathies à forces de cisaillement élevées. Un monitoring en temps réel du VWF pourrait notamment avoir un intérêt en cardiologie interventionnelle pour les techniques percutanées utilisées pour le traitement du rétrécissement aortique.La dernière partie de ce travail porte sur le développement d’un test ELISA pour le diagnostic des formes acquises ou constitutionnelles de maladie de Willebrand secondaire à une protéolyse excessive du VWF par l’ADAMTS13. Ce test pourrait constituer une alternative intéressante aux actuelles méthodes électrophorétiques pour le diagnostic et la prise en charge de ces pathologies hémorragiques.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Protéolyse du facteur Willebrand et cardiopathies à forces de cisaillement élevées : nouvelles approches diagnostiques et thérapeutiques
Protéolyse du facteur von Willebrand et cardiopathies à forces de cisaillement élevées: nouvelles approches diagnostiques et thérapeutiques Dans la première partie de ce travail, nous mettons en évidence l’intérêt d’une immunothérapie spécifique à base d’anticorps monoclonal pour la prévention de la dégradation du facteur von Willebrand (VWF) sous assistance circulatoire mécanique à flux continu. Via un anticorps monoclonal murin ciblant le domaine D4 du VWF et inhibant partiellement l’interaction VWF-ADAMTS13, une inhibition partielle de la dégradation du VWF est observée sur sang total dans un modèle ex-vivo d’assistance circulatoire mécanique.Dans la seconde partie, nous avons étudié l’influence de soudaines variations de l’intensité des forces de cisaillement sur la multimérisation du VWF dans 3 modèles in-vivo: un modèle lapin de sténose de l’aorte ascendante, à l’initiation d’une assistance ventriculaire gauche par une pompe à flux continu chez des patients en insuffisance cardiaque terminale et lors d’un remplacement valvulaire aortique par voie percutané chez des patients avec un rétrécissement aortique sévère. Les variations observées du profil multimérique sont très dynamiques survenant quelques minutes après les modifications des conditions de flux. Notre étude met ainsi en évidence une nouvelle application potentielle du VWF comme biomarqueur d’anomalies de flux dans les cardiopathies à forces de cisaillement élevées. Un monitoring en temps réel du VWF pourrait notamment avoir un intérêt en cardiologie interventionnelle pour les techniques percutanées utilisées pour le traitement du rétrécissement aortique.La dernière partie de ce travail porte sur le développement d’un test ELISA pour le diagnostic des formes acquises ou constitutionnelles de maladie de Willebrand secondaire à une protéolyse excessive du VWF par l’ADAMTS13. Ce test pourrait constituer une alternative intéressante aux actuelles méthodes électrophorétiques pour le diagnostic et la prise en charge de ces pathologies hémorragiques.
- Open Access
- 10 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 903-914
Modeling response to high-purity von Willebrand factor: toward tailored dosing during surgery in von Willebrand disease
In surgical settings, managing von Willebrand disease (VWD) often requires von Willebrand factor (VWF) concentrate administration, and close monitoring of factor VIII (FVIII) and VWF to balance bleeding control with the risk of excessive factor elevation. This management is further complicated by VWD-related variability and the pharmacokinetic (PK) impact of VWF products, containing or not exogenous FVIII. We hypothesized that building a PK model based on high-purity VWF concentrates may clarify the VWF-FVIII relationship by eliminating exogenous FVIII interference. Our aim was to characterize the PK/pharmacodynamic (PD) relationship and variability of a high-purity VWF concentrate in patients with VWD undergoing surgery. A retrospective analysis was conducted on patients treated perioperatively with a high-purity plasma-derived VWF concentrate (Wilfactin, Laboratoire Français du Fractionnement et des Biotechnologies, France), nearly devoid of FVIII, from January 2016 to December 2018. Data were analyzed using a population PK/PD modeling approach. VWF antigen (VWF:Ag) was prioritized as it better reflects VWF-FVIII binding capacity rather than VWF activity, which measures platelet interaction. Covariates influencing VWF:Ag and FVIII:C PK/PD were analyzed. Seventy-four patients undergoing 99 surgeries were included. The model revealed substantial variability in VWF:Ag and FVIII:C volume of distribution, clearance, and baseline levels. Covariates such as age, bodyweight, VWD type, blood group, and VWF propeptide significantly affected PK/PD parameters. Interindividual variability in PK parameters (eg, clearance, volume), ranged from 25.3% to 73.8%. High interindividual PK/PD variability was observed with high-purity VWF concentrate. This highlights the need to develop a robust dose-adjustment model to optimize factor concentrate utilization, avoid unnecessary waste, and reduce the frequency of laboratory monitoring.
- 10 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 903-914
Open AccessModeling response to high-purity von Willebrand factor: toward tailored dosing during surgery in von Willebrand disease
In surgical settings, managing von Willebrand disease (VWD) often requires von Willebrand factor (VWF) concentrate administration, and close monitoring of factor VIII (FVIII) and VWF to balance bleeding control with the risk of excessive factor elevation. This management is further complicated by VWD-related variability and the pharmacokinetic (PK) impact of VWF products, containing or not exogenous FVIII. We hypothesized that building a PK model based on high-purity VWF concentrates may clarify the VWF-FVIII relationship by eliminating exogenous FVIII interference. Our aim was to characterize the PK/pharmacodynamic (PD) relationship and variability of a high-purity VWF concentrate in patients with VWD undergoing surgery. A retrospective analysis was conducted on patients treated perioperatively with a high-purity plasma-derived VWF concentrate (Wilfactin, Laboratoire Français du Fractionnement et des Biotechnologies, France), nearly devoid of FVIII, from January 2016 to December 2018. Data were analyzed using a population PK/PD modeling approach. VWF antigen (VWF:Ag) was prioritized as it better reflects VWF-FVIII binding capacity rather than VWF activity, which measures platelet interaction. Covariates influencing VWF:Ag and FVIII:C PK/PD were analyzed. Seventy-four patients undergoing 99 surgeries were included. The model revealed substantial variability in VWF:Ag and FVIII:C volume of distribution, clearance, and baseline levels. Covariates such as age, bodyweight, VWD type, blood group, and VWF propeptide significantly affected PK/PD parameters. Interindividual variability in PK parameters (eg, clearance, volume), ranged from 25.3% to 73.8%. High interindividual PK/PD variability was observed with high-purity VWF concentrate. This highlights the need to develop a robust dose-adjustment model to optimize factor concentrate utilization, avoid unnecessary waste, and reduce the frequency of laboratory monitoring.
- Open Access
- 5 December 2024
- Published by Wiley in European Journal of Haematology
- Vol. 114 (3) , 508-516
ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B
Objectives: To assess the real‐world efficacy and safety of recombinant factor IX albumin fusion protein (rIX‐FP) in patients with hemophilia B (HB) in France.Methods: Data on dosing frequency, weekly consumption, and bleeds before‐and‐after switching to rIX‐FP, were collected from December 2021 to February 2024. Annualized (spontaneous) bleeding rates [A(s)BRs] were calculated only in patients on prophylaxis with a follow‐up ≥ 6 months.Results: This interim analysis focused on 77 patients ≥ 12 years; 62 (81%) had severe HB. After switching to rIX‐FP, the infusion interval was 14 (7–14) days. Weekly consumption was 43 (35.5–53) IU/kg. ABRs and AsBRs were 0.5 (0–1.9) and 0 (0–0.7) (n = 63) at 18.2 (12.3–21.9) months of follow‐up. Prophylactic efficacy of rIX‐FP was considered ‘Excellent’/‘Good’ in 65/68 (95%) patients. Among the 43 patients previously treated with rFIXFc, 21 increased the infusion interval from 7 (7–11) days with rFIXFc to 14 (7–14) days with rIX‐FP; 33/43 (77%) reduced weekly factor IX (FIX) consumption from 59.95 (46.35–77.93) to 42.5 (35.88–50.25) IU/kg. Patients maintained good protection against bleeds.Conclusion: This analysis confirmed that switching to rIX‐FP allows for reducing injection frequency and FIX consumption while maintaining good bleed protection.
- 5 December 2024
- Published by Wiley in European Journal of Haematology
- Vol. 114 (3) , 508-516
Open AccessORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B
Objectives: To assess the real‐world efficacy and safety of recombinant factor IX albumin fusion protein (rIX‐FP) in patients with hemophilia B (HB) in France.Methods: Data on dosing frequency, weekly consumption, and bleeds before‐and‐after switching to rIX‐FP, were collected from December 2021 to February 2024. Annualized (spontaneous) bleeding rates [A(s)BRs] were calculated only in patients on prophylaxis with a follow‐up ≥ 6 months.Results: This interim analysis focused on 77 patients ≥ 12 years; 62 (81%) had severe HB. After switching to rIX‐FP, the infusion interval was 14 (7–14) days. Weekly consumption was 43 (35.5–53) IU/kg. ABRs and AsBRs were 0.5 (0–1.9) and 0 (0–0.7) (n = 63) at 18.2 (12.3–21.9) months of follow‐up. Prophylactic efficacy of rIX‐FP was considered ‘Excellent’/‘Good’ in 65/68 (95%) patients. Among the 43 patients previously treated with rFIXFc, 21 increased the infusion interval from 7 (7–11) days with rFIXFc to 14 (7–14) days with rIX‐FP; 33/43 (77%) reduced weekly factor IX (FIX) consumption from 59.95 (46.35–77.93) to 42.5 (35.88–50.25) IU/kg. Patients maintained good protection against bleeds.Conclusion: This analysis confirmed that switching to rIX‐FP allows for reducing injection frequency and FIX consumption while maintaining good bleed protection.
- Open Access
- 25 June 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (4) , 485-492
Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study
Objectives: Haemophilia B (HB), characterised by deficient factor IX (FIX), leads to spontaneous bleeds. Severe cases require prophylactic FIX replacement. This post hoc analysis assessed the first spontaneous bleeds among previously untreated patients (PUPs) with HB treated with recombinant FIX Fc fusion protein (rFIXFc) (NCT02234310) to identify factors influencing bleeds.Methods: Subjects included paediatric PUPs with HB (≤2 IU/dL endogenous FIX). Analyses described treatment patterns (on demand [OD] vs. prophylaxis) and prophylaxis type (started on vs. switched to prophylaxis). Kaplan–Meier analyses assessed the time to first spontaneous bleed, including median time to event and fitting models with predictors for treatment regimen and/or baseline age.Results: PUPs B‐LONG enrolled 33 subjects. Baseline age did not influence the time to first spontaneous bleed for any rFIXFc regimen. Those who started on prophylaxis with rFIXFc (n = 11), compared with those treated OD (n = 22), had an extended time to first spontaneous bleed. Starting prophylaxis afforded a 93% reduced risk of first spontaneous bleed versus starting OD (hazard ratio [95% confidence interval]: 0.071 [0.009–0.592]) (p = .015).Conclusion: rFIXFc prophylaxis, particularly starting early, reduced the risk of bleeding and delayed time to first spontaneous bleed compared with rFIXFc OD. Hence, initial treatment regimens impact bleed patterns in paediatric PUPs.
- 25 June 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (4) , 485-492
Open AccessProphylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study
Objectives: Haemophilia B (HB), characterised by deficient factor IX (FIX), leads to spontaneous bleeds. Severe cases require prophylactic FIX replacement. This post hoc analysis assessed the first spontaneous bleeds among previously untreated patients (PUPs) with HB treated with recombinant FIX Fc fusion protein (rFIXFc) (NCT02234310) to identify factors influencing bleeds.Methods: Subjects included paediatric PUPs with HB (≤2 IU/dL endogenous FIX). Analyses described treatment patterns (on demand [OD] vs. prophylaxis) and prophylaxis type (started on vs. switched to prophylaxis). Kaplan–Meier analyses assessed the time to first spontaneous bleed, including median time to event and fitting models with predictors for treatment regimen and/or baseline age.Results: PUPs B‐LONG enrolled 33 subjects. Baseline age did not influence the time to first spontaneous bleed for any rFIXFc regimen. Those who started on prophylaxis with rFIXFc (n = 11), compared with those treated OD (n = 22), had an extended time to first spontaneous bleed. Starting prophylaxis afforded a 93% reduced risk of first spontaneous bleed versus starting OD (hazard ratio [95% confidence interval]: 0.071 [0.009–0.592]) (p = .015).Conclusion: rFIXFc prophylaxis, particularly starting early, reduced the risk of bleeding and delayed time to first spontaneous bleed compared with rFIXFc OD. Hence, initial treatment regimens impact bleed patterns in paediatric PUPs.
- Open Access
- 13 May 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 981-987
Severe haemorrhages leading to a diagnosis of rare bleeding disorder occur at a very young age: A study from the FranceCoag network
Introduction: In the context of severe unexplained haemorrhage (SH), it is usual to seek haematological evaluation and investigate for an inherited rare bleeding disorder (IRBD). In such circumstances, appropriate screen can discriminate between IRBD and suspected child abuse. Yet, little information is available about the frequency of SH in the population of patients with IRBD.Aim: To collect epidemiologic data about SH and IRBD.Method: The database of the FranceCoag network has collected information about IRBD since January 2004. Based on data gathered up to 16 March 2022, a retrospective search was conducted for of SH events having occurred before or at the time of IRBD diagnosis. Demographics and diagnosis circumstances were retrieved, as well as information about SH, defined as any life‐threatening bleeding or intracranial haemorrhage.Results: Among the 13,433 patients of the database, 109 (0.8%) fulfilled inclusion criteria including a known date of IRBD diagnosis, haemophilia A or B (HA/HB) being the most frequent (82.5%). IRBD was discovered as a consequence of an SH event in 82.6% of the cases while CNS was involved in 55%. Severe and moderate HA/HB and other severe IRBD presented significantly more intracranial haemorrhage (p < .02) and a lower age at diagnosis (p = .03).Conclusions: These data support that any unusual SH should raise a suspicion of IRBD. Particularly before 1‐year of age, it is suggested to first confirm moderate or severe haemophilia and severe IRBD by standard coagulation tests (APTT, PT and fibrinogen), combined with a clotting FXIII assay as first‐line investigation. Subsequent assays of coagulation factors should be performed in the case of abnormal values, in second‐line investigation.
- 13 May 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 981-987
Open AccessSevere haemorrhages leading to a diagnosis of rare bleeding disorder occur at a very young age: A study from the FranceCoag network
Introduction: In the context of severe unexplained haemorrhage (SH), it is usual to seek haematological evaluation and investigate for an inherited rare bleeding disorder (IRBD). In such circumstances, appropriate screen can discriminate between IRBD and suspected child abuse. Yet, little information is available about the frequency of SH in the population of patients with IRBD.Aim: To collect epidemiologic data about SH and IRBD.Method: The database of the FranceCoag network has collected information about IRBD since January 2004. Based on data gathered up to 16 March 2022, a retrospective search was conducted for of SH events having occurred before or at the time of IRBD diagnosis. Demographics and diagnosis circumstances were retrieved, as well as information about SH, defined as any life‐threatening bleeding or intracranial haemorrhage.Results: Among the 13,433 patients of the database, 109 (0.8%) fulfilled inclusion criteria including a known date of IRBD diagnosis, haemophilia A or B (HA/HB) being the most frequent (82.5%). IRBD was discovered as a consequence of an SH event in 82.6% of the cases while CNS was involved in 55%. Severe and moderate HA/HB and other severe IRBD presented significantly more intracranial haemorrhage (p < .02) and a lower age at diagnosis (p = .03).Conclusions: These data support that any unusual SH should raise a suspicion of IRBD. Particularly before 1‐year of age, it is suggested to first confirm moderate or severe haemophilia and severe IRBD by standard coagulation tests (APTT, PT and fibrinogen), combined with a clotting FXIII assay as first‐line investigation. Subsequent assays of coagulation factors should be performed in the case of abnormal values, in second‐line investigation.
- 27 October 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (10) , 826-841
Shear Force-Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia
BACKGROUND: Thrombocytopenia has been consistently described in patients with extracorporeal membrane oxygenation (ECMO) and associated with poor outcome. However, the prevalence and underlying mechanisms remain largely unknown, and a device-related role of ECMO in thrombocytopenia has been hypothesized. This study aimed to investigate the mechanisms underlying thrombocytopenia in ECMO patients. METHODS: In a prospective cohort of 107 ECMO patients, we investigated platelet count, functions, and glycoprotein shedding. In an ex vivo mock circulatory ECMO loop, we assessed platelet responses and VWF (von Willebrand factor)–GP Ibα (glycoprotein Ibα) interactions at low- and high-flow rates, in the presence or absence of red blood cells. The clearance of human platelets subjected or not to ex vivo perfusion was studied using an in vivo transfusion model in NOD/SCID (nonobese diabetic/severe combined Immunodeficient) mice. RESULTS: In ECMO patients, we observed a time-dependent decrease in platelet count starting 1 hour after device onset, with a mean drop of 7%, 35%, and 41% at 1, 24, and 48 hours post-ECMO initiation ( P =0.00013, P P P =0.002) and an increase in soluble GP Ibα plasma levels (before: 5.6±3.3 versus 24 hours post-ECMO: 10.8±4.1 µg/mL; P <0.0001). GP Ibα shedding was also observed ex vivo and was unaffected by (1) red blood cells, (2) the coagulation potential, (3) an antibody blocking VWF–GP Ibα interaction, (4) an antibody limiting VWF degradation, and (5) supraphysiological VWF plasma concentrations. In contrast, GP Ibα shedding was dependent on rheological conditions, with a 2.8-fold increase at high- versus low-flow rates. Platelets perfused at high-flow rates before being transfused to immunodeficient mice were eliminated faster in vivo with an accelerated clearance of GP Ibα–negative versus GP Ibα–positive platelets. CONCLUSIONS: ECMO-associated shear forces induce GP Ibα shedding and thrombocytopenia due to faster clearance of GP Ibα–negative platelets. Inhibiting GP Ibα shedding could represent an approach to reduce thrombocytopenia during ECMO.
- 27 October 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (10) , 826-841
Shear Force-Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia
BACKGROUND: Thrombocytopenia has been consistently described in patients with extracorporeal membrane oxygenation (ECMO) and associated with poor outcome. However, the prevalence and underlying mechanisms remain largely unknown, and a device-related role of ECMO in thrombocytopenia has been hypothesized. This study aimed to investigate the mechanisms underlying thrombocytopenia in ECMO patients. METHODS: In a prospective cohort of 107 ECMO patients, we investigated platelet count, functions, and glycoprotein shedding. In an ex vivo mock circulatory ECMO loop, we assessed platelet responses and VWF (von Willebrand factor)–GP Ibα (glycoprotein Ibα) interactions at low- and high-flow rates, in the presence or absence of red blood cells. The clearance of human platelets subjected or not to ex vivo perfusion was studied using an in vivo transfusion model in NOD/SCID (nonobese diabetic/severe combined Immunodeficient) mice. RESULTS: In ECMO patients, we observed a time-dependent decrease in platelet count starting 1 hour after device onset, with a mean drop of 7%, 35%, and 41% at 1, 24, and 48 hours post-ECMO initiation ( P =0.00013, P P P =0.002) and an increase in soluble GP Ibα plasma levels (before: 5.6±3.3 versus 24 hours post-ECMO: 10.8±4.1 µg/mL; P <0.0001). GP Ibα shedding was also observed ex vivo and was unaffected by (1) red blood cells, (2) the coagulation potential, (3) an antibody blocking VWF–GP Ibα interaction, (4) an antibody limiting VWF degradation, and (5) supraphysiological VWF plasma concentrations. In contrast, GP Ibα shedding was dependent on rheological conditions, with a 2.8-fold increase at high- versus low-flow rates. Platelets perfused at high-flow rates before being transfused to immunodeficient mice were eliminated faster in vivo with an accelerated clearance of GP Ibα–negative versus GP Ibα–positive platelets. CONCLUSIONS: ECMO-associated shear forces induce GP Ibα shedding and thrombocytopenia due to faster clearance of GP Ibα–negative platelets. Inhibiting GP Ibα shedding could represent an approach to reduce thrombocytopenia during ECMO.